Novo Nordisk Follows Eli Lilly’s Lead, Lowering Insulin Prices up to 75%
MARCH 14, 2023
Novo Nordisk can afford the price cuts prices to several branded and non-branded insulins. Flattening revenue for the pharmaceutical giant’s insulin products is offset by demand for diabetes and obesity drugs from its semaglutide franchise, which continues to grow by leaps and bounds.
Let's personalize your content